# Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia

> **NCT07186894** · — · ACTIVE_NOT_RECRUITING · sponsor: **Central Hospital, Nancy, France** · enrollment: 5000 (estimated)

## Conditions studied

- Bacteriemia
- Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection

## Interventions

- **DRUG:** Antistaphylococcal penicillins
- **DRUG:** Cefazolin

## Key facts

- **NCT ID:** NCT07186894
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2000-01-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07186894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07186894, "Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07186894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*